{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-016254","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.878094+00:00","generated_at":"2026-06-15T14:09:06.607914+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Therapeutics Q1 net loss $30.5M, cash $316M; FHD-286 mUM data expected Q2 2023","bullets":["Net loss of $30.5M for Q1 2023, compared to $26.9M loss in Q1 2022; no product revenue.","Cash and equivalents $316M as of March 31, 2023, providing runway into second half of 2025.","Phase 1 dose escalation of FHD-286 in metastatic uveal melanoma continues; top-line data expected Q2 2023.","FDA clinical hold on FHD-286 in AML/MDS; regulatory update expected Q2 2023.","Collaboration revenue $5.3M, up from $3.9M; Loxo@Lilly collaboration progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-016254","json":"https://secwatch.observer/filing/0001628280-23-016254.json","markdown":"https://secwatch.observer/filing/0001628280-23-016254.md","text":"https://secwatch.observer/filing/0001628280-23-016254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/0001628280-23-016254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/fhtx-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:09:06.607914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4503f041267508c9aca476f79133aabd87e0ea2c","claim":"Foghorn Therapeutics Inc. reported the quarter ended March 31, 2023 results: revenue $5.3 million, net income $30.5 million.","evidence_excerpt":"First Quarter 2023 Financial Highlights • Strong Balance Sheet and Cash Runway. As of March 31, 2023, the Company had $316.0 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025 . • Collaboration Revenues. Collaboration revenue was $5.3 million for the three months ended March 31, 2023, compared to $3.9 million for the three months ended March 31, 2022. The increase year-over-year was primarily driven by revenue recognized under the Lilly collaboration agreement. • Research and Development Expenses. Research and development expenses were $30.0 million for the three months ended March 31, 2023, compared to $24.5 million for the three months ended March 31, 2022. This increase was primarily due to costs associated with continued investment in R&D personnel and platform and early-stage research investments. • General and Administrative Expenses. General and administrative expenses were $8.6 million for the three months ende","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/0001628280-23-016254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.3 million"},{"label":"Net income","value":"$30.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}